News

September 3, 2019

LLS Calls on Stakeholders to Combat Soaring Cancer Care Costs

News

The rising cost of cancer care in the United States is increasingly being passed on to patients, some of whom defer or skip treatments because they can’t afford them, says ... Read more

August 30, 2019

Trial of Cutaneous T-cell Lymphoma Therapy WP1220 Fully Enrolled

News

A Phase 2 clinical trial of WP1220, a potential topical treatment of cutaneous T-cell lymphoma (CTCL) lesions, has reached full patient enrollment. Developed by Moleculin Biotech, WP1220 is an inhibitor ... Read more

August 27, 2019

Cirmtuzumab-Imbruvica Combo Trial Enrolling CLL, SLL Patients for Phase 2

News

Following promising early efficacy results for a cirmtuzumab–Imbruvica treatment combo, a Phase 2 clinical trial has now been opened to people with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The opening of ... Read more

August 23, 2019

FDA Grants Priority Review to Zanubrutinib as Treatment for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted for review BeiGene‘s application requesting the approval of zanubrutinib for treating people with mantle cell lymphoma who received at least one ... Read more

August 22, 2019August 22, 2019

Lymphoma Research Foundation to Honor MSK’s Anas Younes at September Gala

News

The Lymphoma Research Foundation will honor Anas Younes, an oncologist and lymphoma expert at Memorial Sloan Kettering (MSK) Cancer Center, with its Distinguished Leadership Award next month at the nonprofit’s annual gala. The ... Read more

August 20, 2019

Clinical Trials in China Will Test Abexinostat for DLBCL, Follicular Lymphoma

News

Xynomic Pharma is launching two pivotal clinical trials in China to test its investigational HDAC inhibitor, abexinostat, as a third-line therapy for two types of non-Hodgkin’s lymphoma: diffuse large B-cell lymphoma (DLBCL) and follicular ... Read more

August 16, 2019

Imbruvica Use Expanded in EU to Combo Treatments for Chronic Lymphocytic Leukemia and Waldenström’s Macroglobulinemia

News

The European Commission (EC) has expanded the use of Imbruvica (ibrutinib) to cover combinations with Gazyva (obinutuzumab) for previously untreated adults with chronic lymphocytic leukemia (CLL), and with MabThera (rituximab) for ... Read more

August 13, 2019September 4, 2019

Medicare Now Covers CAR T-cell Therapy for Certain Lymphomas and Leukemias

News

Medicare will provide nationwide coverage for CAR T-cell therapies, an innovative anti-cancer treatment, for certain types of lymphoma and leukemia, the Centers for Medicare & Medicaid Services (CMS) has announced. ... Read more

August 9, 2019September 9, 2019

Cerdulatinib Alone or with Rituxan Effective in Previously Treated Follicular Lymphoma, Data Show

News

Treatment with the oral therapy cerdulatinib alone or in combination with Rituxan (rituximab) shows durable efficacy, including some complete responses, in patients with follicular lymphoma who failed prior medications, according ... Read more

August 8, 2019September 10, 2019

FDA Asked to Place Abexinostat, Possible Follicular Lymphoma Treatment, on Fast Track

News

Xynomic Pharmaceuticals has filed a request with U.S. Food and Drug Administration (FDA) asking that abexinostat, its lead therapeutic candidate for relapsed or refractory follicular lymphoma, be given fast track designation. The ... Read more